Pavmed Inc (PAVM) Stock Price, Quote & News

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.pavmed.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

BigJuicy Mar. 20 at 2:45 PM

$PAVM unfortunately slow bleed out to $6.50 where the big investors are buying 1.5 million shares in their recent proxy vote. I will be buying at 6.5, patience until the.

1 · Reply

dmc4321 Mar. 20 at 8:58 AM

$LUCD & $PAVM @Tom__Brady Are you Walter Mitty? If we were to look at your timeline would we see you PUMPING and EXTOLLING the virtues of winners or LOSERS? What do you think? Everybody knows who I am. It is not a secret. You however are modelling yourself after a fictional character. So people can make of that what they may.

1 · Reply

chuckjackson Mar. 19 at 5:25 PM

$PAVM chatgpt is amazing. S-1 filing: likely ~1–3 weeks after March 27. Effective: ~3–4 weeks → early May 2026 (fast track). Sometimes companies: Pre-file or confidentially draft the S-1 before the vote. If that happened here (no evidence yet): 👉 Timeline could compress significantly

1 · Reply

xx007xx Mar. 19 at 5:01 PM

$LUCD $PAVM absolute 🤡 if you only knew…

0 · Reply

chuckjackson Mar. 19 at 4:05 PM

$PAVM it was originally because of the 31x leverage from lucd. At some point, there were 1M shares outstanding in pavm and they own 31M shares lucd. At that time, if lucd doubled, then pavm would benefit 61x on a per share basis. Also, the low float fostered more extreme price movements. But in a week, the dynamics will change when the 4.6M shares are released.

1 · Reply

chuckjackson Mar. 19 at 4:00 PM

$PAVM stike two. One at-bat left

0 · Reply

BigJuicy Mar. 19 at 1:28 PM

$LUCD taking side bets on the price once LCD comes out. My guess is 2.50$. $PAVM 25$…. Who will be closest?

1 · Reply

Ironbow Mar. 19 at 1:16 PM

$LUCD $PAVM Dave switched accounts; dmc4321 and LaPlates are just spreading FUD; Fear uncertainty and doubt… classic tactic…. Ignore 👇🏻

2 · Reply

LPlates Mar. 19 at 1:12 PM

$LUCD $PAVM Please explain why at the CAC meeting for EsoGuard all the participants used the BEST3 trial from Cyted Health as proof of "Real World Evidence" that a non invasive sampling device can be a valuable triage tool. Just search the transcript for BEST3. During the meeting, the panelists frequently used Cyted Health's BEST3 trial (the landmark randomized controlled trial for the Cytosponge-TFF3) as the primary benchmark for "clinical utility." So while you ATTEMPT to rubbish Cyted Healths diagnostics test it has been out longer and done more paid tests. That's just a FACT. So unless you consider yourself more of an expert than the specialists on the CAC call. (Did you turn down your invitation to speak 🤔?) Maybe you should accept you are DUMBER than a rock and stay quiet.

1 · Reply

xx007xx Mar. 19 at 12:13 PM

$LUCD $PAVM Cyted is ANOTHER SPONGE on a STRING. Medtronic showed that clinical viability is trash. Why on earth do you continue to peddle this trash on here? You should know better than that, yet here you are, as always. CYTED IS NOT THE SAME. CYTED IS a CYTOSPONGE EQUIVALENT. Your credibility with this is ZERO and viewed as the resident troll and that’s all. It doesn’t take a genius to see this so not sure why you spend day in and day out bashing it. Obviously you’re a scorned ex lover of their organization and want to try and pull it through the mud constantly. Pathetic. Truly sad.

1 · Reply

PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

LUCD

Mar 12, 2026, 9:01 AM EDT - 9 days ago

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

LUCD

Feb 4, 2026, 8:01 AM EST - 6 weeks ago

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

LUCD

Jan 21, 2026, 3:40 PM EST - 2 months ago

Should you chase the rally in PAVmed stock after it quadrupled on Wednesday?

Jan 21, 2026, 8:00 AM EST - 2 months ago

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

LUCD

Dec 30, 2025, 9:01 AM EST - 2 months ago

PAVmed Announces Reverse Stock Split

Dec 9, 2025, 8:01 AM EST - 3 months ago

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

LUCD

Nov 20, 2025, 8:15 AM EST - 4 months ago

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

LUCD

Nov 13, 2025, 8:15 AM EST - 4 months ago

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LUCD

Nov 13, 2025, 8:00 AM EST - 4 months ago

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

LUCD

Nov 12, 2025, 8:00 AM EST - 4 months ago

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

LUCD

Oct 30, 2025, 8:01 AM EDT - 5 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

LUCD

Oct 29, 2025, 8:01 AM EDT - 5 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

LUCD

Oct 15, 2025, 8:01 AM EDT - 5 months ago

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

LUCD

Oct 7, 2025, 8:01 AM EDT - 5 months ago

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

Sep 16, 2025, 8:01 AM EDT - 6 months ago

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

LUCD

Sep 11, 2025, 9:17 AM EDT - 6 months ago

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

LUCD

Sep 10, 2025, 8:00 AM EDT - 6 months ago

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

LUCD

Sep 9, 2025, 4:01 PM EDT - 6 months ago

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

LUCD

Sep 5, 2025, 9:16 AM EDT - 7 months ago

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

LUCD

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

LUCD

Aug 26, 2025, 8:01 AM EDT - 7 months ago

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

LUCD

Aug 14, 2025, 8:00 AM EDT - 7 months ago

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

LUCD

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

LUCD

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

LUCD

Jul 31, 2025, 8:01 AM EDT - 8 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

LUCD

Jul 30, 2025, 8:01 AM EDT - 8 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

LUCD

Jul 30, 2025, 8:00 AM EDT - 8 months ago

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

LUCD

Jul 16, 2025, 7:31 AM EDT - 8 months ago

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

LUCD

Jun 24, 2025, 8:01 AM EDT - 9 months ago

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Jun 18, 2025, 12:02 PM EDT - 9 months ago

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

LUCD

Jun 3, 2025, 8:31 AM EDT - 10 months ago

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

May 27, 2025, 7:31 AM EDT - 10 months ago

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

LUCD

May 15, 2025, 8:01 AM EDT - 11 months ago

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 14, 2025, 8:01 AM EDT - 11 months ago

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 1, 2025, 8:31 AM EDT - 11 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

LUCD

Apr 30, 2025, 8:31 AM EDT - 11 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

LUCD

Apr 24, 2025, 8:01 AM EDT - 11 months ago

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

LUCD

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

LUCD

Mar 27, 2025, 8:01 AM EDT - 1 year ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

LUCD

Mar 25, 2025, 8:01 AM EDT - 1 year ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 8:01 AM EDT - 1 year ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

LUCD

Mar 20, 2025, 8:31 AM EDT - 1 year ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

LUCD

Mar 18, 2025, 8:31 AM EDT - 1 year ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

LUCD

Mar 13, 2025, 7:36 AM EDT - 1 year ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

LUCD

Mar 10, 2025, 9:01 AM EDT - 1 year ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

LUCD

Mar 5, 2025, 4:45 PM EST - 1 year ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

LUCD

Mar 4, 2025, 8:25 AM EST - 1 year ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

LUCD

Feb 27, 2025, 8:31 AM EST - 1 year ago

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

LUCD

Feb 25, 2025, 8:31 AM EST - 1 year ago

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

LUCD

BigJuicy Mar. 20 at 2:45 PM

$PAVM unfortunately slow bleed out to $6.50 where the big investors are buying 1.5 million shares in their recent proxy vote. I will be buying at 6.5, patience until the.

1 · Reply

dmc4321 Mar. 20 at 8:58 AM

1 · Reply

chuckjackson Mar. 19 at 5:25 PM

1 · Reply

xx007xx Mar. 19 at 5:01 PM

$LUCD $PAVM absolute 🤡 if you only knew…

0 · Reply

chuckjackson Mar. 19 at 4:05 PM

1 · Reply

chuckjackson Mar. 19 at 4:00 PM

$PAVM stike two. One at-bat left

0 · Reply

BigJuicy Mar. 19 at 1:28 PM

$LUCD taking side bets on the price once LCD comes out. My guess is 2.50$. $PAVM 25$…. Who will be closest?

1 · Reply

Ironbow Mar. 19 at 1:16 PM

$LUCD $PAVM Dave switched accounts; dmc4321 and LaPlates are just spreading FUD; Fear uncertainty and doubt… classic tactic…. Ignore 👇🏻

2 · Reply

LPlates Mar. 19 at 1:12 PM

1 · Reply

xx007xx Mar. 19 at 12:13 PM

1 · Reply

dmc4321 Mar. 19 at 6:25 AM

$LUCD & $PAVM This is just wrong. EsoCheck has got FDA approval and EsoGuard got a FDA Breakthrough Device Designation which has nothing to do with the 510 pathway. Cyted Health also has FDA approval since February 2024, and raised $44M in August 2025 to launch in the USA. It was Cyted Healths data from their UK clinical trial that was used as the basis for discussion at EsoGuards CAC meeting in September 2025 for "real world evidence" as EsoGuard did not have that evidence. There is also Previse which is now owned by Castle Biosciences which has a clear focus on esophageal cancers and has a large sales and marketing force already calling on the GI's etc as they SUCESSFULLY sell TissueCypher. So there is well funded EXISTING SUCESSFUL competitors in this niche. After approval you need to sell EsoGuard and the only concrete data we have is LUCD's 29 salespeople only managed to sell less than 2 covered tests a week in 1H 2025. That does not scale. AT ALL. MASSIVE DILUTION INCOMING1

1 · Reply

Investor_Scale Mar. 19 at 6:14 AM

$PAVM will this be the day ?!?

0 · Reply

oaksapollo Mar. 18 at 8:12 PM

$PAVM congrats to PAVM on the green close, only green on my screen today. Hope it bodes well for the Moldx document drop tonight.

1 · Reply

Ironbow Mar. 18 at 5:54 PM

$LUCD $PAVM Dmc4321 aka Dave, just woke up from his patty’s day banger !! Ignore

1 · Reply

dmc4321 Mar. 18 at 5:12 PM

$LUCD & $PAVM this response reconsiles my Grok analysis with your Grok analysis. YOU WILL NOT LIKE IT!!! Revised timeline: Draft LCD most likely July–September 2026 (Q3) at the earliest, or potentially later / no draft in 2026 if evidence gaps persist. Consolidated Best Estimate (as of March 18, 2026)Taking both of my prior responses into account — the initial process-flow estimate (optimistic April–May draft tied to the June 9 open meeting) and the subsequent red-team critique (deeper dive into the actual CGS page language, housekeeping revisions, active LCD text, MolDX guidance, and peer-review realities) — here is the reconciled view: Revised timeline: Draft LCD most likely July–September 2026 (Q3) at the earliest, or potentially later / no draft in 2026 if evidence gaps persist. This is a meaningful shift from the original “April or May” prediction, but still within the broader 3–9 month post-CAC window I originally cited. THE LINK SO YOU CAN SEE THE FULL CHAT https://x.com/i/grok/share/0cd15e7cf5ad43dc8c3184593a6c256

2 · Reply

dmc4321 Mar. 18 at 4:43 PM

$LUCD & $PAVM @TheBearVsTheBull I decided to get Grok to comment on my Gemini based analysis. Grok surfaced something totally new to me. 4. Alignment with Evidence Requirements and the Cyted vs. EsoGuard RWE Tension Gemini correctly flags the peer-review issue, but the active LCD language is STRICTER than described. L39276/L39262 EXPLICITLY REQUIRES "clinical validity demonstrated in peer-reviewed literature (with biological/molecular basis for management change) plus successful Technical Assessment before any coverage can be proposed. Current tests (including EsoGuard) are stated as non-covered unless ALL CRITERIA —including peer-reviewed CV—are met. " cms.gov +1 The December 2025 EsoGuard 12,000-patient RWE was submitted after the CAC and explicitly noted in the transcript as "not yet in the peer-reviewed literature." med.noridianmedicare.com TO ACCESS THE CHAT https://x.com/i/grok/share/602bf80d672c48cc9a4bb29df28634a0

1 · Reply

BigJuicy Mar. 18 at 4:33 AM

$LUCD Thursday yet? $PAVM

0 · Reply

dmc4321 Mar. 17 at 6:43 AM

$LUCD & $PAVM @RetiredMD A LIE This is just a MASS TESTING EVENT. It is announced today Tuesday, and ends tomorrow Wednesday. “Go get the early testing, go get ahead of it and live a long life,” Turner said. Free screenings are available for St. George firefighters through WEDNESDAY." Expect more of this crap as Lishan and Dennis try and create a narrative of progress to make up for THE TOTAL LACK OF PROGRESS.

1 · Reply

chuckjackson Mar. 16 at 8:08 PM

$PAVM so is Lishan giving up control of pavm? Insiders hold 60+% (with Lishan having a large holding) of the 1.5M shares outstanding. Whoever owns the preferred shares will own 4.6M shares when converted which means they will then control pavm.

3 · Reply

dmc4321 Mar. 16 at 5:22 PM

$LUCD & $PAVM IT actually is NOT taking any longer than normal if you consider the FACTS and ignore the liars like @PortfolioMgmt23 1. RESUBMISSIONS both take longer as you need to get agreement with all parties that contributed to the original REJECTION that the quality of the information is sufficient to overturn that REJECTION. 2. They do NOT GET PRIORITY. Explicitly stated. And in a lot of cases are buried behind original submissions as the workload is less and a decision already exists. 3. During the CAC they discussed Cyted Healths real world PEER REVIEWED data as the Gold Standard, as EsoGuard does NOT HAVE EQUIVALENT data. EsoGuard is missing the most critical data as it has been submitted but has not been peer reviewed. Ask yourself this. Would CMS be embarassed and would peoples jobs be at risk if there was the EXACT data they need waiting for peer review but CMS jumped the gun and then the peer review process concluded that the data was NOT GOOD ENOUGH? JUST FACTS.

0 · Reply

Ironbow Mar. 16 at 12:22 PM

$LUCD $PAVM #Dave~#dmc4321 👇🏻🏆

0 · Reply

dmc4321 Mar. 16 at 5:27 AM

$LUCD & $PAVM Normally there would be a Press Release late this week to try and create a narrative of "Progress" before the Conference Call. Lishan and Dennis have pushed the CC back to Thursday from the usual Wednesday in the hope that draft approval will be announced, it wont BTW. I suggest you ask this series of questions as at this stage they look at retail shareholders as total cuckolds. 1. You said you would focus on testing patients that would be covered under the population at risk when Esoguard gets approved. You did 500 a qtr in Q1 & Q2 of 2025. How many did you do in Q3 and Q 4 of 2025? The vast majority of your tests were done in mass testing events (3 nurses 200 people tested) how many additional nurses and sales people do you need to hire immediately if you are only testing 10 patients per location as flights, hotels etc remain the same. Is it 50 nurses per 200 tests? What is the largest number of patients tested that paid the full rate $1983 in one day at one location?

0 · Reply

Market Cap	10.28M
Revenue (ttm)	3.00M
Net Income (ttm)	39.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,326.33%
Debt to Equity Ratio	0.00

Volume	14,100
Avg Vol	1,241,072
Day's Range	N/A - N/A
Shares Out	984,000.00
Stochastic %K	32%
Beta	0.90
Analysts	Sell
Price Target	$285.25